Výsledky vyhledávání - "Lang A O'Dondi"

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study

Autor: Antoni Vilaseca, Félix Guerrero, Daniel Zainfeld, Neal D. Shore, Oscar Rodriguez Faba, Richard P. Meijer, Alfred Alfred Witjes, Autumn Jackson McRee, Anna Kalota, Nicole L. Stone, Josh David Lauring, Wei Zhu, Neil Beeharry, Lang A O'Dondi, Gautam Jayram

Publikováno v: Journal of Clinical Oncology. 41:TPS583-TPS583

TPS583 Background: Treatment options are limited for pts with NMIBC and MIBC who experience disease recurrence or who are ineligible for or refuse standard of care. Erda, an oral selective pan-FGFR tyrosine kinase inhibitor, is approved in adults wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7da2f9f31740935fec019d1d4baecb48
https://doi.org/10.1200/jco.2023.41.6_suppl.tps583

Zobrazit plný text záznamu

MP13-17 SUNRISE-2: A PHASE 3, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY OF TAR-200 IN COMBINATION WITH CETRELIMAB VERSUS CONCURRENT CHEMORADIOTHERAPY IN PARTICIPANTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

Autor: X. Li, Stephen B. Williams, Kirk A. Keegan, Wei Zhu, Lang A O'Dondi, Daniel E. Spratt, N. Beeharry, Christopher Cutie, Milin Acharya, Rachel Stewart, Bradley Raybold

Publikováno v: Journal of Urology. 206

INTRODUCTION AND OBJECTIVE:The standard of care for patients with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant chemotherapy and radical cystectomy (RC) or chemoradiotherapy (CRT). ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7f248813394b2cdae80c86911255196
https://doi.org/10.1097/ju.0000000000001994.17

Zobrazit plný text záznamu

A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder

Autor: Christopher Cutie, N. Beeharry, Stephen B. Williams, Milin Acharya, Lang A O'Dondi, Daniel E. Spratt, Wei Zhu, Bradley Raybold, Kirk A Keegan, X. Li

Publikováno v: Journal of Clinical Oncology. 39:TPS4586-TPS4586

TPS4586 Background: The standard of care for patients with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant chemotherapy and radical cystectomy (RC) or chemoradiotherapy (CRT). However, RC is associated with potential morbidity or mortal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7fb675da287ed2795d6c88f8e6a878a0
https://doi.org/10.1200/jco.2021.39.15_suppl.tps4586

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání